Drug Res (Stuttg) 2023; 73(08): 473-475
DOI: 10.1055/a-2111-6649
Short Communication

Altered Gene Expression of Cytochrome P450 and ABC Transporter in Human Hepatocellular Carcinoma HepG2 Cells Exposed to Bardoxolone Methyl

Katsuhito Nagai
1   Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University, Nishikiori-kita, Tondabayashi, Japan
,
Shuhei Fukuno
1   Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University, Nishikiori-kita, Tondabayashi, Japan
,
Takeshi Miura
2   Pharmaceutical Education Support Center, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Koshien, Bancho, Nishinomiya, Japan
,
Eri Yasuda-Imanishi
1   Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University, Nishikiori-kita, Tondabayashi, Japan
,
Hiroki Konishi
1   Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University, Nishikiori-kita, Tondabayashi, Japan
› Author Affiliations

Abstract

Bardoxolone methyl (BX) is expected to be an innovate therapeutic agent for chronic kidney disease (CKD). The aim of the present study was to examine whether the expression of subtypes of cytochrome P450 (CYP) and ABC transporters was altered in human hepatocellular carcinoma HepG2 cells by exposure to BX. The expression of mRNAs for CYP1A2, CYP2E1, P-glycoprotein, multidrug resistance-associated protein 1–3, and breast cancer resistance protein was significantly increased by exposure of HepG2 cells to BX, while the expression of CYP3A4 mRNA was significantly decreased under the same conditions. BX had no significant effect on the expression of mRNAs for CYP2C9 and CYP2C19 in HepG2 cells. In conclusion, this study demonstrated that the gene expression of several CYPs and ABC transporters in HepG2 cells was altered when exposed to BX, suggesting the need to pay careful attention to drug-drug interactions in patients receiving BX for CKD treatment.



Publication History

Received: 14 April 2023

Accepted: 13 June 2023

Article published online:
17 August 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Hong DS, Kurzrock R, Supko JG. et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 2012; 18: 3396-3406
  • 2 Reisman SA, Chertow GM, Hebbar S. et al. Bardoxolone methyl decreases megalin and activates Nrf2 in the kidney. J Am Soc Nephrol 2012; 23: 1663-1673
  • 3 Rendic SP. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Arch Toxicol 2021; 95: 1535-1546
  • 4 Di YM, Li CG, Xue CC. et al. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des 2008; 14: 1723-1742
  • 5 Zhou L, Naraharisetti SB, Liu L. et al. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 2010; 31: 228-242
  • 6 Prasad N, Singh H, Jaiswal A. et al. Overexpression of P-glycoprotein and MRP-1 are pharmacogenomic biomarkers to determine steroid resistant phenotype in childhood idiopathic nephrotic syndrome. Pharmacogenomics J 2021; 21: 566-573
  • 7 Griffin BR, Faubel S, Edelstein CL. Biomarkers of drug-induced kidney toxicity. Ther Drug Monit 2019; 41: 213-226
  • 8 Nies AT, König J, Pfannschmidt M. et al. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 2001; 94: 492-499
  • 9 Tian J, Hu J, Liu G. et al. Altered Gene expression of ABC transporters, nuclear receptors and oxidative stress signaling in zebrafish embryos exposed to CdTe quantum dots. Environ Pollut 2019; 244: 588-599
  • 10 Emeka PM, Ibrahim HIM, Alhaider IA. et al. Subchronic administration of mitoxantrone and the influence of enzyme inhibitors on its induced cardiotoxicity in mice: role of NRF-2/CYP2E1. Eur Rev Med Pharmacol Sci 2021; 25: 7806-7822